Sarepta Therapeutics shares jumped 60 percent after reporting promising results from an early-stage study testing its gene therapy in patients with Duchenne muscular dystrophy (DMD).
Britain said it had no intention of legalizing cannabis after a former leader of Prime Minister Theresa May’s party said the government had “irreversibly lost” the battle to drive the drug off the streets.
Roche is paying $2.4 billion to buy the rest of Foundation Medicine, raising the Swiss drugmaker’s bet on the U.S. genomic profiling group’s ability to personalize cancer care.
Americans listed healthcare as the most important problem facing the country, according to Reuters/Ipsos polling.
Valeant Pharmaceuticals International Inc.’s plaque psoriasis treatment did not get approval from U.S. health regulators.
The U.S. FDA approved for marketing DreaMed Diabetes’ Advisor Pro software to help manage diabetes treatment.
Addiction to video games has been recognized by the World Health Organization as a mental health disorder.
Theranos Inc. founder Elizabeth Holmes and the embattled blood-testing company’s former president were indicted on charges that they engaged in schemes to defraud investors, doctors and patients, the U.S. Justice Department announced.
Teva Pharmaceutical Inc. will discontinue a trial testing the company’s drug for the treatment of chronic cluster headache.
AIDS researchers in Hong Kong say new research – tested on mice – indicates a functional cure for HIV, eventually leading to a new antibody that could be used for prevention and treatment.
Novartis touted safety and efficacy of the company’s biosimilar copies of Johnson & Johnson’s Remicade and Amgen’s Enbrel for treating autoimmune diseases.
Kentucky’s attorney general sued Walgreens Boots Alliance Inc., accusing the company of playing a role in propagating an opioid epidemic in the state.
GlaxoSmithKline’s two-drug treatment for HIV met its main goal in late-stage studies, scoring key points in the company’s rivalry with Gilead in the medical field.
Mylan NV said U.S. health regulators were unable to approve the company’s generic version of GlaxoSmithKline’s blockbuster inhaled lung drug Advair for the second time, as they found “minor deficiencies” in the treatment.
Eli Lilly and Co. said the company’s drug to treat the autoimmune disease lupus met the main goal of a mid-stage trial, positioning the drugmaker to begin a larger study in 2018.
Sanofi believes that it can make a comeback and re-establish a leading position in the competitive cancer drug market on the back of its immunotherapy drugs and efforts in new areas such as molecular oncology.
Johnson & Johnson has accepted private equity firm Platinum Equity’s $2.1 billion buyout offer for the company’s LifeScan unit.
The head of the World Health Organization cautioned against declaring victory too early in Congo’s Ebola epidemic, despite encouraging signs that it may be brought under control.
Eli Lilly and AstraZeneca discontinued late-stage trials testing their Alzheimer’s treatment, the latest among a slew of drugmakers to stop developing treatments for the memory-robbing disease.